A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge

Waranyoo Phoolcharoen, John M. Dye, Jacquelyn Kilbourne, Khanrat Piensook, William D. Pratt, Charles J. Arntzen, Qiang Chen, Hugh S. Mason, Melissa Herbst-Kralovetz

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Ebola hemorrhagic fever is an acute and often deadly disease caused by Ebola virus (EBOV). The possible intentional use of this virus against human populations has led to design of vaccines that could be incorporated into a national stockpile for biological threat reduction. We have evaluated the immunogenicity and efficacy of an EBOV vaccine candidate in which the viral surface glycoprotein is biomanufactured as a fusion to a monoclonal antibody that recognizes an epitope in glycoprotein, resulting in the production of Ebola immune complexes (EICs). Although antigen-antibody immune complexes are known to be efficiently processed and presented to immune effector cells, we found that codelivery of the EIC with Toll-like receptor agonists elicited a more robust antibody response in mice than did EIC alone. Among the compounds tested, polyinosinic:polycytidylic acid (PIC, a Toll-like receptor 3 agonist) was highly effective as an adjuvant agent. After vaccinating mice with EIC plus PIC, 80% of the animals were protected against a lethal challenge with live EBOV (30,000 LD 50 of mouse adapted virus). Surviving animals showed a mixed Th1/Th2 response to the antigen, suggesting this may be important for protection. Survival after vaccination with EIC plus PIC was statistically equivalent to that achieved with an alternative viral vector vaccine candidate reported in the literature. Because nonreplicating subunit vaccines offer the possibility of formulation for cost-effective, long-term storage in biothreat reduction repositories, EIC is an attractive option for public health defense measures.

Original languageEnglish (US)
Pages (from-to)20695-20700
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume108
Issue number51
DOIs
StatePublished - Dec 20 2011

Fingerprint

Ebolavirus
Subunit Vaccines
Antigen-Antibody Complex
Ebola Hemorrhagic Fever
Ebola Vaccines
Toll-Like Receptor 3
Viral Vaccines
Viruses
Poly I-C
Toll-Like Receptors
Membrane Glycoproteins
Antibody Formation
Epitopes
Glycoproteins
Vaccination
Vaccines
Public Health
Monoclonal Antibodies
Antigens
Costs and Cost Analysis

Keywords

  • Antibody-antigen fusion
  • Ebola glycoprotein
  • Ebola vaccine
  • Immunopotentiator
  • Protective antibody

ASJC Scopus subject areas

  • General

Cite this

A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. / Phoolcharoen, Waranyoo; Dye, John M.; Kilbourne, Jacquelyn; Piensook, Khanrat; Pratt, William D.; Arntzen, Charles J.; Chen, Qiang; Mason, Hugh S.; Herbst-Kralovetz, Melissa.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, No. 51, 20.12.2011, p. 20695-20700.

Research output: Contribution to journalArticle

Phoolcharoen, Waranyoo ; Dye, John M. ; Kilbourne, Jacquelyn ; Piensook, Khanrat ; Pratt, William D. ; Arntzen, Charles J. ; Chen, Qiang ; Mason, Hugh S. ; Herbst-Kralovetz, Melissa. / A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. In: Proceedings of the National Academy of Sciences of the United States of America. 2011 ; Vol. 108, No. 51. pp. 20695-20700.
@article{8b69b71d7e9447b9aa8e97562316f19c,
title = "A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge",
abstract = "Ebola hemorrhagic fever is an acute and often deadly disease caused by Ebola virus (EBOV). The possible intentional use of this virus against human populations has led to design of vaccines that could be incorporated into a national stockpile for biological threat reduction. We have evaluated the immunogenicity and efficacy of an EBOV vaccine candidate in which the viral surface glycoprotein is biomanufactured as a fusion to a monoclonal antibody that recognizes an epitope in glycoprotein, resulting in the production of Ebola immune complexes (EICs). Although antigen-antibody immune complexes are known to be efficiently processed and presented to immune effector cells, we found that codelivery of the EIC with Toll-like receptor agonists elicited a more robust antibody response in mice than did EIC alone. Among the compounds tested, polyinosinic:polycytidylic acid (PIC, a Toll-like receptor 3 agonist) was highly effective as an adjuvant agent. After vaccinating mice with EIC plus PIC, 80{\%} of the animals were protected against a lethal challenge with live EBOV (30,000 LD 50 of mouse adapted virus). Surviving animals showed a mixed Th1/Th2 response to the antigen, suggesting this may be important for protection. Survival after vaccination with EIC plus PIC was statistically equivalent to that achieved with an alternative viral vector vaccine candidate reported in the literature. Because nonreplicating subunit vaccines offer the possibility of formulation for cost-effective, long-term storage in biothreat reduction repositories, EIC is an attractive option for public health defense measures.",
keywords = "Antibody-antigen fusion, Ebola glycoprotein, Ebola vaccine, Immunopotentiator, Protective antibody",
author = "Waranyoo Phoolcharoen and Dye, {John M.} and Jacquelyn Kilbourne and Khanrat Piensook and Pratt, {William D.} and Arntzen, {Charles J.} and Qiang Chen and Mason, {Hugh S.} and Melissa Herbst-Kralovetz",
year = "2011",
month = "12",
day = "20",
doi = "10.1073/pnas.1117715108",
language = "English (US)",
volume = "108",
pages = "20695--20700",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "51",

}

TY - JOUR

T1 - A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge

AU - Phoolcharoen, Waranyoo

AU - Dye, John M.

AU - Kilbourne, Jacquelyn

AU - Piensook, Khanrat

AU - Pratt, William D.

AU - Arntzen, Charles J.

AU - Chen, Qiang

AU - Mason, Hugh S.

AU - Herbst-Kralovetz, Melissa

PY - 2011/12/20

Y1 - 2011/12/20

N2 - Ebola hemorrhagic fever is an acute and often deadly disease caused by Ebola virus (EBOV). The possible intentional use of this virus against human populations has led to design of vaccines that could be incorporated into a national stockpile for biological threat reduction. We have evaluated the immunogenicity and efficacy of an EBOV vaccine candidate in which the viral surface glycoprotein is biomanufactured as a fusion to a monoclonal antibody that recognizes an epitope in glycoprotein, resulting in the production of Ebola immune complexes (EICs). Although antigen-antibody immune complexes are known to be efficiently processed and presented to immune effector cells, we found that codelivery of the EIC with Toll-like receptor agonists elicited a more robust antibody response in mice than did EIC alone. Among the compounds tested, polyinosinic:polycytidylic acid (PIC, a Toll-like receptor 3 agonist) was highly effective as an adjuvant agent. After vaccinating mice with EIC plus PIC, 80% of the animals were protected against a lethal challenge with live EBOV (30,000 LD 50 of mouse adapted virus). Surviving animals showed a mixed Th1/Th2 response to the antigen, suggesting this may be important for protection. Survival after vaccination with EIC plus PIC was statistically equivalent to that achieved with an alternative viral vector vaccine candidate reported in the literature. Because nonreplicating subunit vaccines offer the possibility of formulation for cost-effective, long-term storage in biothreat reduction repositories, EIC is an attractive option for public health defense measures.

AB - Ebola hemorrhagic fever is an acute and often deadly disease caused by Ebola virus (EBOV). The possible intentional use of this virus against human populations has led to design of vaccines that could be incorporated into a national stockpile for biological threat reduction. We have evaluated the immunogenicity and efficacy of an EBOV vaccine candidate in which the viral surface glycoprotein is biomanufactured as a fusion to a monoclonal antibody that recognizes an epitope in glycoprotein, resulting in the production of Ebola immune complexes (EICs). Although antigen-antibody immune complexes are known to be efficiently processed and presented to immune effector cells, we found that codelivery of the EIC with Toll-like receptor agonists elicited a more robust antibody response in mice than did EIC alone. Among the compounds tested, polyinosinic:polycytidylic acid (PIC, a Toll-like receptor 3 agonist) was highly effective as an adjuvant agent. After vaccinating mice with EIC plus PIC, 80% of the animals were protected against a lethal challenge with live EBOV (30,000 LD 50 of mouse adapted virus). Surviving animals showed a mixed Th1/Th2 response to the antigen, suggesting this may be important for protection. Survival after vaccination with EIC plus PIC was statistically equivalent to that achieved with an alternative viral vector vaccine candidate reported in the literature. Because nonreplicating subunit vaccines offer the possibility of formulation for cost-effective, long-term storage in biothreat reduction repositories, EIC is an attractive option for public health defense measures.

KW - Antibody-antigen fusion

KW - Ebola glycoprotein

KW - Ebola vaccine

KW - Immunopotentiator

KW - Protective antibody

UR - http://www.scopus.com/inward/record.url?scp=84855483647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855483647&partnerID=8YFLogxK

U2 - 10.1073/pnas.1117715108

DO - 10.1073/pnas.1117715108

M3 - Article

C2 - 22143779

AN - SCOPUS:84855483647

VL - 108

SP - 20695

EP - 20700

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 51

ER -